NUR2474 Pharmacology for Professional Nursing — Practice Exam 2025/2026
Rasmussen University
College of Nursing
NUR2474 Pharmacology for Professional Nursing
Comprehensive Practice Examination
2025/2026 Academic Year | 75 Questions | NCLEX-Aligned
Examination Instructions
This 75-question comprehensive practice examination is designed to evaluate proficiency in pharmacologic
principles for pre-licensure nursing students. The exam covers all major pharmacology domains tested on
Rasmussen course examinations and aligned with NCLEX-RN competencies.
Format: Multiple-choice single-best-answer questions with rationales. Correct answers are displayed in
bold green. Pharmacologic rationales are presented in italic.
Time: Approximately 90–120 minutes | Passing Score: 75–80%
Pharmacokinetics & Pharmacodynamics Fundamentals (Questions 1–8)
1. A nurse is reviewing the mechanism of action of a newly prescribed medication. Which
phase of pharmacokinetics describes the movement of a drug from its site of administration
into the bloodstream?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: Absorption is the process by which a drug moves from its site of administration into the
systemic circulation. The rate and extent of absorption depend on the route of administration, drug
formulation, solubility, and surface area available for absorption. Drugs administered intravenously
have 100% bioavailability because they bypass the absorption phase entirely.
2. A patient with liver cirrhosis is prescribed a medication that undergoes extensive hepatic
metabolism. The nurse should anticipate which alteration in the drug's pharmacokinetics?
A. Increased absorption
B. Decreased metabolism leading to drug accumulation
C. Enhanced renal excretion
D. Reduced protein binding
Rationale: The liver is the primary organ for drug metabolism, primarily through the cytochrome
P450 (CYP) enzyme system. In liver cirrhosis, hepatocyte damage reduces metabolic capacity, leading to
decreased first-pass metabolism and reduced clearance of hepatically metabolized drugs. This results in
prolonged half-life and potential drug accumulation, increasing the risk of toxicity.
Page 1
, NUR2474 Pharmacology for Professional Nursing — Practice Exam 2025/2026
3. A nurse is administering a highly protein-bound drug (95%) to a patient with
hypoalbuminemia. What is the most significant clinical concern?
A. Increased renal clearance of the drug
B. Higher free (unbound) drug concentration increasing risk of toxicity
C. Decreased volume of distribution
D. Enhanced therapeutic effect at standard doses
Rationale: Protein-bound drugs are primarily attached to albumin and are pharmacologically
inactive. In hypoalbuminemia, fewer binding sites are available, resulting in a higher proportion of free
(active) drug in circulation. This increases the drug's pharmacologic effect and risk of adverse effects at
standard doses, requiring careful monitoring and possible dosage reduction.
4. A medication has a half-life of 6 hours. How long will it take for the drug to reach
approximately steady-state concentration with repeated dosing?
A. 12 hours
B. 18 hours
C. 24 hours
D. 30 hours
Rationale: Steady-state concentration is achieved when the amount of drug absorbed equals the
amount eliminated. It typically takes approximately 4 to 5 half-lives to reach steady state. For a drug
with a 6-hour half-life, steady state is reached in about 24 to 30 hours (4 × 6 = 24 hours, 5 × 6 = 30
hours). This principle is essential for determining when to evaluate drug efficacy and adjust dosages.
5. Which pharmacokinetic parameter describes the volume of fluid required to contain the
total amount of drug in the body at the same concentration as in the blood?
A. Bioavailability
B. Volume of distribution
C. Clearance
D. Therapeutic index
Rationale: Volume of distribution (Vd) is a theoretical value that relates the total amount of drug in the
body to the measured plasma concentration. A high Vd indicates extensive tissue distribution, while a
low Vd suggests the drug remains primarily in the plasma. This parameter helps determine loading
doses and predicts how effectively hemodialysis can remove a drug.
6. The therapeutic index (TI) of a drug is calculated as the ratio of which two values?
A. ED50 to LD50
B. TD50 to ED50
C. LD50 to ED50
D. ED100 to LD1
Rationale: The therapeutic index (TI) is defined as the ratio of the median lethal dose (LD50) to the
median effective dose (ED50). A higher TI indicates a wider margin of safety, meaning a larger dose is
required to produce toxicity relative to the effective therapeutic dose. Drugs with a narrow TI (such as
digoxin or warfarin) require close monitoring of serum drug levels and patient response.
Page 2
, NUR2474 Pharmacology for Professional Nursing — Practice Exam 2025/2026
7. A patient takes an oral medication that undergoes significant first-pass metabolism. Which
route of administration would bypass this effect?
A. Oral
B. Sublingual
C. Intramuscular
D. Subcutaneous
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract travel through the
portal vein to the liver before reaching systemic circulation, where they may be significantly
metabolized. Sublingual administration bypasses the GI tract and hepatic portal system because venous
drainage from the oral mucosa enters the superior vena cava directly, delivering the drug to the systemic
circulation without first-pass loss.
8. A drug that acts as a competitive antagonist at a receptor site would produce which effect
when an agonist is also present?
A. Enhanced agonist effect
B. Shifts the dose-response curve to the right
C. Shifts the dose-response curve to the left
D. Irreversible blockade of all receptors
Rationale: Competitive antagonists bind reversibly to the same receptor site as the agonist, competing
for occupancy. This competition shifts the dose-response curve of the agonist to the right, meaning a
higher concentration of agonist is required to achieve the same effect. The maximal response can still be
achieved if sufficient agonist is present. Noncompetitive antagonists, in contrast, reduce the maximal
achievable response.
Medication Safety & Nursing Process (Questions 9–15)
9. Which of the "Rights of Medication Administration" is confirmed when the nurse scans the
patient's wristband and compares it to the medication administration record (MAR)?
A. Right drug
B. Right dose
C. Right patient
D. Right route
Rationale: The Right Patient is verified using at least two patient identifiers (e.g., name and date of
birth), most commonly by scanning the patient's wristband and cross-referencing with the electronic
medication administration record (eMAR). This critical safety check prevents medication errors related
to patient misidentification, which are among the most common and preventable adverse events in
healthcare.
10. A nurse is about to administer an intravenous medication and notices the solution is
cloudy with visible particulate matter. What is the nurse's priority action?
A. Shake the solution to disperse the particles
B. Administer the medication through a filter needle
C. Do not administer the medication and notify the pharmacist
D. Administer the medication and document the observation
Page 3
Rasmussen University
College of Nursing
NUR2474 Pharmacology for Professional Nursing
Comprehensive Practice Examination
2025/2026 Academic Year | 75 Questions | NCLEX-Aligned
Examination Instructions
This 75-question comprehensive practice examination is designed to evaluate proficiency in pharmacologic
principles for pre-licensure nursing students. The exam covers all major pharmacology domains tested on
Rasmussen course examinations and aligned with NCLEX-RN competencies.
Format: Multiple-choice single-best-answer questions with rationales. Correct answers are displayed in
bold green. Pharmacologic rationales are presented in italic.
Time: Approximately 90–120 minutes | Passing Score: 75–80%
Pharmacokinetics & Pharmacodynamics Fundamentals (Questions 1–8)
1. A nurse is reviewing the mechanism of action of a newly prescribed medication. Which
phase of pharmacokinetics describes the movement of a drug from its site of administration
into the bloodstream?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: Absorption is the process by which a drug moves from its site of administration into the
systemic circulation. The rate and extent of absorption depend on the route of administration, drug
formulation, solubility, and surface area available for absorption. Drugs administered intravenously
have 100% bioavailability because they bypass the absorption phase entirely.
2. A patient with liver cirrhosis is prescribed a medication that undergoes extensive hepatic
metabolism. The nurse should anticipate which alteration in the drug's pharmacokinetics?
A. Increased absorption
B. Decreased metabolism leading to drug accumulation
C. Enhanced renal excretion
D. Reduced protein binding
Rationale: The liver is the primary organ for drug metabolism, primarily through the cytochrome
P450 (CYP) enzyme system. In liver cirrhosis, hepatocyte damage reduces metabolic capacity, leading to
decreased first-pass metabolism and reduced clearance of hepatically metabolized drugs. This results in
prolonged half-life and potential drug accumulation, increasing the risk of toxicity.
Page 1
, NUR2474 Pharmacology for Professional Nursing — Practice Exam 2025/2026
3. A nurse is administering a highly protein-bound drug (95%) to a patient with
hypoalbuminemia. What is the most significant clinical concern?
A. Increased renal clearance of the drug
B. Higher free (unbound) drug concentration increasing risk of toxicity
C. Decreased volume of distribution
D. Enhanced therapeutic effect at standard doses
Rationale: Protein-bound drugs are primarily attached to albumin and are pharmacologically
inactive. In hypoalbuminemia, fewer binding sites are available, resulting in a higher proportion of free
(active) drug in circulation. This increases the drug's pharmacologic effect and risk of adverse effects at
standard doses, requiring careful monitoring and possible dosage reduction.
4. A medication has a half-life of 6 hours. How long will it take for the drug to reach
approximately steady-state concentration with repeated dosing?
A. 12 hours
B. 18 hours
C. 24 hours
D. 30 hours
Rationale: Steady-state concentration is achieved when the amount of drug absorbed equals the
amount eliminated. It typically takes approximately 4 to 5 half-lives to reach steady state. For a drug
with a 6-hour half-life, steady state is reached in about 24 to 30 hours (4 × 6 = 24 hours, 5 × 6 = 30
hours). This principle is essential for determining when to evaluate drug efficacy and adjust dosages.
5. Which pharmacokinetic parameter describes the volume of fluid required to contain the
total amount of drug in the body at the same concentration as in the blood?
A. Bioavailability
B. Volume of distribution
C. Clearance
D. Therapeutic index
Rationale: Volume of distribution (Vd) is a theoretical value that relates the total amount of drug in the
body to the measured plasma concentration. A high Vd indicates extensive tissue distribution, while a
low Vd suggests the drug remains primarily in the plasma. This parameter helps determine loading
doses and predicts how effectively hemodialysis can remove a drug.
6. The therapeutic index (TI) of a drug is calculated as the ratio of which two values?
A. ED50 to LD50
B. TD50 to ED50
C. LD50 to ED50
D. ED100 to LD1
Rationale: The therapeutic index (TI) is defined as the ratio of the median lethal dose (LD50) to the
median effective dose (ED50). A higher TI indicates a wider margin of safety, meaning a larger dose is
required to produce toxicity relative to the effective therapeutic dose. Drugs with a narrow TI (such as
digoxin or warfarin) require close monitoring of serum drug levels and patient response.
Page 2
, NUR2474 Pharmacology for Professional Nursing — Practice Exam 2025/2026
7. A patient takes an oral medication that undergoes significant first-pass metabolism. Which
route of administration would bypass this effect?
A. Oral
B. Sublingual
C. Intramuscular
D. Subcutaneous
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract travel through the
portal vein to the liver before reaching systemic circulation, where they may be significantly
metabolized. Sublingual administration bypasses the GI tract and hepatic portal system because venous
drainage from the oral mucosa enters the superior vena cava directly, delivering the drug to the systemic
circulation without first-pass loss.
8. A drug that acts as a competitive antagonist at a receptor site would produce which effect
when an agonist is also present?
A. Enhanced agonist effect
B. Shifts the dose-response curve to the right
C. Shifts the dose-response curve to the left
D. Irreversible blockade of all receptors
Rationale: Competitive antagonists bind reversibly to the same receptor site as the agonist, competing
for occupancy. This competition shifts the dose-response curve of the agonist to the right, meaning a
higher concentration of agonist is required to achieve the same effect. The maximal response can still be
achieved if sufficient agonist is present. Noncompetitive antagonists, in contrast, reduce the maximal
achievable response.
Medication Safety & Nursing Process (Questions 9–15)
9. Which of the "Rights of Medication Administration" is confirmed when the nurse scans the
patient's wristband and compares it to the medication administration record (MAR)?
A. Right drug
B. Right dose
C. Right patient
D. Right route
Rationale: The Right Patient is verified using at least two patient identifiers (e.g., name and date of
birth), most commonly by scanning the patient's wristband and cross-referencing with the electronic
medication administration record (eMAR). This critical safety check prevents medication errors related
to patient misidentification, which are among the most common and preventable adverse events in
healthcare.
10. A nurse is about to administer an intravenous medication and notices the solution is
cloudy with visible particulate matter. What is the nurse's priority action?
A. Shake the solution to disperse the particles
B. Administer the medication through a filter needle
C. Do not administer the medication and notify the pharmacist
D. Administer the medication and document the observation
Page 3
